PharmaCyte Biotech, Inc. (PMCB) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -786.85K | -979.52K | -1.99M | -1.04M | -509.89K | -1.05M | -373.3K | -332.96K | -177.1K | -1.98M | 342.96K | -288.39K |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -54.32% | 7.13% | -434.15% | -212.46% | -187.91% | 46.85% | -208.85% | -15.45% | 67.31% | -5.59% | 131.63% | 75.8% |
| Net Income | 746.86K | -7.42M | -8.36M | 11.75M | -3.05M | -1.47M | 23.42M | 1.35M | -619.54K | 2.79M | -3.18M | -126.34K |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 771.52K | 60.49K | 60.49K | 63.94K | 72.86K | 119.16K | 222.68K | 0 | 674.69K | 0 | 0 | -638.07K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -2.28M | 6.25M | 7.33M | -14.11M | 2.04M | 421.34K | -24.14M | -1.77M | -368K | -4.22M | 2.9M | 643.95K |
| Working Capital Changes | -20.77K | 129.74K | -1.02M | 1.26M | 422.2K | -125.67K | 125.67K | 87.15K | 135.74K | -554.61K | 630.62K | -167.93K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 178.74K | 469.71K | 66K | -85.74K | 136.35K | -205.36K | 164.58K | -94.83K | 358.04K | -591.97K | 589.85K | -317.65K |
| Cash from Investing | 5M | -3M | 0 | 0 | 0 | 7M | -7M | -5T | -5M | -643.25K | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 2M | 0 | 0 | 0 | 0 | 0 | 0 | -5T | 0 | -643.25K | 0 | 0 |
| Cash from Financing | 543.78K | 6.21M | 0 | -171.54K | -3.95M | -10.74M | -10.17M | -10.7M | -7.04M | 748.69K | 6.28M | -4.31M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 645.13K | 1000K | 0 | -171.54K | -1000K | -1000K | -1000K | -1000K | -1000K | 748.69K | 1000K | -1000K |
| Dividends Paid | -101.36K | -61.25K | 0 | 0 | 0 | -16.19M | 0 | -22.46T | 0 | 0 | -319.85K | 0 |
| Share Repurchases | -401.63K | 0 | 0 | -171.54K | -3.95M | -10.74M | -10.17M | -10.7M | -7.04M | -164.95K | -26.46M | -4.31M |
| Other Financing | 0 | 0 | 0 | 0 | 0 | 16.19M | 0 | 22.46T | 0 | 0 | -1.94M | 0 |
| Net Change in Cash | 4.76M | 2.23M | -1.99M | -1.21M | -4.46M | -11.8M | -17.54M | -11.03M | -12.21M | -1.24M | 6.62M | -4.6M |
| Free Cash Flow | -786.85K | -979.52K | -1.99M | -1.04M | -509.89K | -1.05M | -373.3K | -332.96K | -177.1K | -1.98M | 342.96K | -288.39K |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -54.32% | 7.13% | -434.15% | -212.46% | -187.91% | 46.85% | -208.85% | -15.45% | 67.31% | -5.59% | 131.63% | 75.8% |
| FCF per Share | -0.08 | -0.14 | -0.29 | -0.15 | -0.07 | -0.14 | -0.05 | -0.04 | -0.02 | -0.23 | 0.07 | -0.06 |
| FCF Conversion (FCF/Net Income) | 0.51x | 0.13x | 0.24x | -0.09x | 0.17x | 0.72x | -0.02x | -0.25x | 0.29x | -0.71x | -0.11x | 2.29x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.6K | 0 |